Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia

Current Opinion in Infectious Diseases

Volumn 15, Issue 2, 2002, Pages 183-194

  Pound, Melanie W ^a   Drew, Richard H ^a   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN A; DOFETILIDE; ECHINOCANDIN; FLUCYTOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

AEROSOL; ASPERGILLUS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; ENVIRONMENTAL FACTOR; FEVER; FOOD AND DRUG ADMINISTRATION; FUNGUS IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTIOUS COMPLICATION; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG MYCOSIS; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PUBLICATION; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; VOMITING;

EID: 0036213640     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200204000-00014     Document Type: Review

References (122)

1. Community-acquired pneumonia. A prospective outpatient study
2. Community-acquired pneumonia: Etiology, epidemiology, and outcome at a teaching hospital in Argentina
3. Etiology of community-acquired pneumonia requiring hospitalization in Japan
4. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome
5. Pulmonary cryptococcosis: Localized and disseminated infections in 27 patients with AIDS
6. Pulmonary complications after bone marrow transplantation: High-resolution CT and pathologic findings
7. Pulmonary infections after bone marrow transplant
8. Use of fiberoptic bronchoscopy in bone marrow transplant recipients
9. Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases
10. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer
11. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients
12. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies
13. Infections in liver transplant recipients
14. Clinical application of immunosuppressive agents in renal transplantation
15. Infectious complications following renal transplantation
16. Opportunistic broncho-pulmonary infections after lung transplantation: Clinical and radiographic findings
17. Infectious complications following isolated lung transplantation
18. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center
19. Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional study
20. Opportunistic fungal pneumonia
21. Antifungal prophylaxis for solid organ transplant recipients: Seeking clarity amidst controversy
22. Pulmonary fungal infection: Emphasis on microbiological spectra, patient outcome, and prognostic factors
23. Fungal pneumonias
24. The spectrum of pulmonary infections in cancer patients
25. Fungal pneumonias. The endemic mycoses
26. Counterpoint: Invasive aspergillosis and the environment: Rethinking our approach to prevention
27. Epidemiology of fungal infections in hematopoietic stem cell transplant recipients in the 1990s
28. Spectrum of Aspergillus infection in lung transplant recipients: Case series and review of the literature
29. The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital
30. Invasive mold infections in allogeneic bone marrow transplant recipients
31. The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis
32. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
33. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis
34. Invasive pulmonary aspergillosis associated with infliximab therapy
35. Aspergillus fumigatus pneumonia during cyclosporine treatment for ulcerative colitis
36. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone
37. Assessing risk factors for systemic fungal infections
38. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
39. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance
40. Thrombocytopenia in liver transplant recipients: Predictors, impact on fungal infections, and role of endogenous thrombopoietin
41. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients
42. Aspergillosis case-fatality rate: Systemic review of literature
43. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis
44. Practice guidelines for the treatment of candidiasis. Infectious diseases society of America
45. Candida colonization in mechanically ventilated patients
46. Prospective study of Candida species in patients at a comprehensive cancer center
47. Epidemiology: Surveillance of fungal infections
48. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy
49. Acute respiratory failure associated with pulmonary cryptococcosis in non-aids patients
50. Practice guideline for the treatment of coccidioidomycosis. Infectious diseases society of America
51. Coccidioidomycosis the initial pulmonary infection and beyond
52. Coccidioidomycosis in non-endemic areas: A case series
53. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996
54. Diagnostic case study: Radiographic findings in pulmonary blastomycosis
55. Cluster of pulmonary infections caused by Cunninghametta bertholletiae in immunocompromised patients
56. Zygomycosis in solid organ transplant recipients
57. Practice guidelines for diseases caused by Aspergillus
58. Use of real-time pcr on blood samples for diagnosis of invasive aspergillosis
59. Frequent false-positive results of Aspergittus latex agglutination test: Transient Aspergillus antigenemia during neutropenia
60. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation
61. Fast, simple and highly sensitive double-rounded polymerase chain reaction assay to detect medically relevant fungi in dermatological specimens
62. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance
63. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials
64. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
65. Prevention of fungal and hepatitis virus infections in liver transplantation
66. Incidence of invasive aspergillosis among solid organ transplant recipients at the Cleveland Clinic in the 1990s
67. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial
68. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis
69. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients
70. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters
71. Nosocomial aspergillosis is waterborne
72. Caspofungin acetate: An antifungal agent
73. Caspofungin
74. In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the echinocandin antifungal caspofungin (Cancidas™ MK-0991)
75. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans
76. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (Lipid aMB), or azoles
77. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
78. Comparative in vitro susceptibility of clinical trial isolates to the echinocandin antifungal caspofungin (Cancidas™, MK-0991)
79. In vitro activity of cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance
80. In vitro activity of echinocandin caspofungin (mk-0991) against refractory clinical isolates of Candida and Aspergillus species
81. Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole
82. Intravenous itraconazole
83. Practice guidelines for the management of patients with histoplasmosis
84. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS
85. Practice guidelines for the management of cryptococcal disease
86. Practice guidelines for the management of patients with blastomycosis
87. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
88. In vitro susceptibility of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole
89. In vitro antifungal activity of voriconazole alone and in combination with flucytosine against Candida species other pathogenic fungi
90. In vitro activities of voriconazole (UK-109, 496) and four other antifungal agents against 400 clinical isolates of Candida spp
91. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
92. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
93. Use of voriconazole to treat invasive fungal infections in solid organ and bone marrow transplant recipients
94. Open, randomized comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis
95. Adjunctive immune therapy for fungal infections
96. The Eurofung Network, Interferon-gamma (IFN) and granulocyte-macrophage colony stimulating factor (GM-CSF) enhance hyphal damage of Aspergillus and Fusarium spp. by human neutrophils (PMN)
97. Role of chemokines in fungal infections
98. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
99. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
100. Penetration of ravuconazole, a new triazole antifungal, into rat tissues
101. Interactions of posaconazole and flucytosine against Cryptococcus neoformans
102. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungat infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST)
103. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
104. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
105. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
106. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
107. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
108. Treatment of murine fusariosis with SCH 56592
109. Pharmacokinetics and pharmacodynamics of posaconazole (SCH 56592) in a neutropenic animal model of invasive pulmonary aspergillosis
110. Posaconazole (POSA) treatment of experimental zygomycosis
111. Safety and tolerance of posaconazole (SCH 56592) in patients with nonmeningeal disseminated coccidioidomycosis
112. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice
113. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens
114. In vitro antifungal activity of FK-463 against Candida spp
115. Comparative antifungal activity of the echinocandin FK 463 against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits
116. Pathological findings in a murine pulmonary aspergillosis model: Treatment with FK 463, amphotericin B and a combination of FK 463 and amphotericin B
117. Synergistic effects of combination of FK463 with amphotericin B: Enhanced efficacy in murine model of invasive pulmonary aspergillosis
118. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species
119. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
120. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp